{"identifier":"nobleid:/w1/20260526/806387A7","arkIdentifier":"ark:/48914/w1/20260526/806387A7","version":1,"workTitle":"Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial","workType":"Journal Article","authors":"Solange Peters, Byoung Chul Cho, Alexander V. Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Konstantin Laktionov, Dmytro Trukhin, Sang-We Kim, Grygorii M. Ursol, Maen Hussein","description":null,"workUrl":null,"existingDoi":"10.1016/j.jtho.2024.09.1381","createdAt":"2026-05-26T02:57:28.306545Z","canonicalUrl":"https://nobleid.org/ark:/48914/w1/20260526/806387A7.v1"}